An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A dose-ranging study of the use of oral naloxone in opioid-related constipation in patients with far-advanced cancer is reported. Naloxone doses were calculated as a percentage of the morphine dose each patient was receiving. Seventeen patients entered the first phase of the study, which had a randomised, double-blind design. Outcome measures were small bowel transit time (SBTT) measured by the lactulose/hydrogen breath test, pain scores and the occurrence of adverse events. One subject was excluded before receiving naloxone. No significant difference between placebo and naloxone occurred in the 14 remaining patients receiving total daily doses of naloxone 10% or less of the 24 h dose of morphine. Two further patients experienced a marked laxative effect with naloxone at 20% of the 24 h dose of morphine. In one of these, SBTT was available and was unchanged from placebo. The other declined to continue with SBTT measurement. Phase two of the study had an open design, in which laxative effects were determined clinically. Naloxone at a maximum dose level of 20% was given to seven patients, up to 40% to two patients and up to 80% to one patient. Four out of the seven patients in the 20% dose level group, and all of the remainder, experienced laxative effects. Two patients experienced symptoms of opioid withdrawal, one of whom also had return of pain. It is concluded that oral naloxone at a daily dose of 20% or more of the prevailing 24 h morphine dose is a potentially valuable therapy for opioid- related constipation. However, opioid withdrawal was observed and it is suggested that initial individual naloxone doses should not exceed 5 mg. Further research is needed into the oral absorption of naloxone, as well as further studies of clinical efficacy and dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements.
Jh, B., Levitt, & Prentiss, R. A. (1975) · PubMed · Cited by 413
Metz, G., Gassull, M. A., Leeds, A. R., Blendis, L. M., & Jenkins, D. J. A. (1976) · Clinical Science · doi:10.1042/cs0500237 · Cited by 221
Treatment of opioid-induced constipation with oral naloxone: A pilot study
Culpepper-Morgan, J. A., Inturrisi, C. E., Portenoy, R. K., Foley, K., Houde, R. W., Marsh, F., & Kreek, M. J. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.106 · Cited by 208
Wikler, A., Fraser, H. F., & Isbell, H. (1953) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)05224-3 · Cited by 163
La Brooy, S. J., Male, P. J., Beavis, A. K., & Misiewicz, J. J. (1983) · Gut · doi:10.1136/gut.24.10.893 · Cited by 151
DISPOSITION OF NALOXONE-7,8-3H IN NORMAL AND NARCOTIC-DEPENDENT MEN
Fishman, J., Roffwarg, H., & Hellman, L. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29707-5 · Cited by 144
Heel, R. C., Brogden, R. N., Speight, T. M., & Avery, G. S. (1978) · Drugs · doi:10.2165/00003495-197815010-00003 · Cited by 140
Oral naloxone in opioid-associated constipation
Sykes, N. P. (1991) · The Lancet · doi:10.1016/0140-6736(91)93162-3 · Cited by 105
Self-citationParolaro, D., Sala, M., & Gori, E. (1977) · European Journal of Pharmacology · doi:10.1016/0014-2999(77)90227-8 · Cited by 85
Control of Alimentary Symptoms in Far Advanced Cancer
Twycross, R., & Lack, S. A. (1986) · Medical Entomology and Zoology · Cited by 61
Cited by
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70040-2 · Cited by 1,243
Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report
Cherny, N., Ripamonti, C., Pereira, J., Davis, C., Fallon, M., McQuay, H., Mercadante, S., Pasternak, G., Ventafridda, V., & for the Expert Working Group of the European Association of Palliative Care Network (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2542 · Cited by 626
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
Thomas, J., Karver, S., Cooney, G. A., Chamberlain, B. H., Watt, C. K., Slatkin, N. E., Stambler, N., Kremer, A. B., & Israel, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707377 · Cited by 595
Opioid-Induced Bowel Dysfunction: Pathophysiology and Potential New Therapies
Kurz, A., & Sessler, D. I. (2003) · Drugs · doi:10.2165/00003495-200363070-00003 · Cited by 587
Incidence, Prevalence, and Management of Opioid Bowel Dysfunction
Pappagallo, M. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00782-6 · Cited by 531
Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review
McNicol, E., Horowicz-Mehler, N., Fisk, R. A., Bennett, K., Gialeli-Goudas, M., Chew, P. W., Lau, J., & Carr, D. (2003) · The Journal of Pain · doi:10.1016/s1526-5900(03)00556-x · Cited by 466
Opioid receptors in the gastrointestinal tract
Holzer, P. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.03.012 · Cited by 377
Selective Postoperative Inhibition of Gastrointestinal Opioid Receptors
Taguchi, A., Sharma, N., Saleem, R. M., Sessler, D. I., Carpenter, R. L., Seyedsadr, M., & Kurz, A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010564 · Cited by 318
Opioid-Induced Constipation: Challenges and Therapeutic Opportunities
Camilleri, M. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.30 · Cited by 262
Meissner, W., Leyendecker, P., Mueller‐Lissner, S., Nadstawek, J., Hopp, M., Ruckes, C., Wirz, S., Fleischer, W., & Reimer, K. (2009) · European Journal of Pain · doi:10.1016/j.ejpain.2008.06.012 · Cited by 257
Oral naloxone reverses opioid-associated constipation
Meissner, W., Schmidt, U., Hartmann, M., Kath, R., & Reinhart, K. (2000) · Pain · doi:10.1016/s0304-3959(99)00185-2 · Cited by 204
“Clinical reports of treating opioid-induced constipation with enteral naloxone are limited to a few studies (Sykes, 1991, 1996; Culpepper-Morgan et al., 1992; Latasch et al., 1997) and not without controversy (Robinson et al., 1991).”
InfluentialPortenoy, R. K., Thomas, J., Moehl Boatwright, M. L., Tran, D., Galasso, F. L., Stambler, N., Von Gunten, C. F., & Israel, R. J. (2008) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2007.12.005 · Cited by 182
“This conclusion gains support from a controlled trial of another opioid antagonist, alvimopan,(17) and earlier experience with oral naloxone.(8,18) In contrast to naloxone,(18) these newer drugs have not been associated with opioid withdrawal or diminished pain control.”
ResultWiffen, P. J., Wee, B., & Moore, R. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003868.pub3 · Cited by 180
Simpson, K., Leyendecker, P., Hopp, M., Müller-Lissner, S., Löwenstein, O., De Andrés, J., Troy Ferrarons, J., Bosse, B., Krain, B., Nichols, T., et al. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802584454 · Cited by 177
Paulson, D. M., Kennedy, D. T., Donovick, R. A., Carpenter, R. L., Cherubini, M., Techner, L., Du, W., Ma, Y., Schmidt, W. K., Wallin, B., et al. (2005) · The Journal of Pain · doi:10.1016/j.jpain.2004.12.001 · Cited by 158
Metadata
- Authors
- Sykes, N.
- Venue
- Palliative Medicine
- Publisher
- SAGE Publications
- Published
- 1996-04
- Volume
- 10
- Issue
- 2
- Pages
- 135-144
- ISSN
- 0269-2163 (ISSN-L)
- 1477-030X
- OpenAlex
- W2113250961
- Cited by
- 197
- References
- 15
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.